344 GENETIC FACTORS INFLUENCE TIME TO UNDETECTABLE PSA IN MEN WITH PROSTATE CANCER TREATED BY RADIOTHERAPY

2011 ◽  
Vol 185 (4S) ◽  
Author(s):  
Sarah Kerns ◽  
Nelson Stone ◽  
Richard Stock ◽  
Yongzhao Shao ◽  
Harry Ostrer ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Genetic Factors

Impact of IGF-I and CYP19 Gene Polymorphisms on the Survival of Patients With Metastatic Prostate Cancer

2006 ◽  
Vol 24 (13) ◽  
pp. 1982-1989 ◽  
Author(s):  
Norihiko Tsuchiya ◽  
Lizhong Wang ◽  
Hiroyoshi Suzuki ◽  
Takehiko Segawa ◽  
Hisami Fukuda ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Bone Metastasis ◽  
Cancer Patients ◽  
Genetic Polymorphisms ◽  
Metastatic Prostate Cancer ◽  
Genetic Factors ◽  
Response To Treatment ◽  
Logrank Test ◽  
Ca Repeat ◽  
Igf I

Purpose The prognosis of metastatic prostate cancer significantly differs among individuals. While various clinical and biochemical prognostic factors for survival have been suggested, the progression and response to treatment of those patients may also be defined by host genetic factors. In this study, we evaluated genetic polymorphisms as prognostic predictors of metastatic prostate cancer. Patients and Methods One hundred eleven prostate cancer patients with bone metastasis at the diagnosis were enrolled in this study. Thirteen genetic polymorphisms were genotyped using polymerase chain reaction-restriction fragment length polymorphism or an automated sequencer with a genotyping software. Results Among the polymorphisms, the long allele (over 18 [CA] repeats) of insulin-like growth factor-I (IGF-I) and the long allele (over seven [TTTA] repeats) of cytochrome P450 (CYP) 19 were significantly associated with a worse cancer-specific survival (P = .016 and .025 by logrank test, respectively). The presence of the long allele of either the IGF-I or CYP19 polymorphisms was an independent risk factor for death (P = .019 or .026, respectively). Furthermore, the presence of the long allele of both the IGF-I and CYP19 polymorphisms was a stronger predictor for survival (P = .001). Conclusion The prognosis of metastatic prostate cancer patients is suggested to be influenced by intrinsic genetic factors. The IGF-I (CA) repeat and CYP19 (TTTA) repeat polymorphisms may be novel predictors in prostate cancer patients with bone metastasis at the diagnosis.

scholarly journals Ethnic Pharmacogenomic Differences in the Management of Asian Patients with Metastatic Prostate Cancer

Cancers ◽  
2022 ◽  
Vol 14 (2) ◽  
pp. 407
Author(s):  
Darren M. C. Poon ◽  
Kuen Chan ◽  
Tim Chan ◽  
Foo-Yiu Cheung ◽  
Daisy Lam ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Ethnic Differences ◽  
Genetic Factors ◽  
Serious Adverse Events ◽  
Pharmacological Management ◽  
Asian Ethnicity ◽  
Asian Patients ◽  
Develop Prostate Cancer ◽  
Drug Tolerability ◽  
Systemic Therapies

Progression to metastatic disease occurs in about half of all men who develop prostate cancer (PC), one of the most common cancers in men worldwide. Androgen deprivation therapy has been the mainstay therapy for patients with metastatic PC (mPC) since the 1940s. In the last decade, there has been unprecedented advancement in systemic therapies, e.g., taxane, androgen-signalling pathway inhibitors, and biomarker-driven targeted therapies for various stages of disease, resulting in overall survival improvement. Adding to ongoing controversies over how best to treat these patients is the recognition that ethnicity may influence prognosis and outcomes. This review discusses recent evidence for the impacts of Asian ethnicity specifically, which includes environmental, sociocultural, and genetic factors, on the approach to pharmacological management of mPC. Clear inter-ethnic differences in drug tolerability, serious adverse events (AEs), and genetic heterogeneity must all be considered when dosing and scheduling for treatment, as well as designing future precision studies in PC.

scholarly journals Differential Gene Expression in Patients With Prostate Cancer and in Patients With Parkinson Disease: an Example of Inverse Comorbidity

2021 ◽  
Author(s):  
Pietro Pepe ◽  
Simona Vetrano ◽  
Rossella Cannarella ◽  
Aldo E Calogero ◽  
Giovanna Marchese ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Causes Of Death ◽  
Genetic Factors ◽  
Target Genes ◽  
Lewy Bodies ◽  
Control Group ◽  
Healthy Donors ◽  
Differential Gene ◽  
Next Generation Sequencing Ngs ◽  
Generation Sequencing

Abstract Prostate cancer (PCa) is one of the leading causes of death in Western countries. Environmental and genetic factors play a pivotal role in PCa etiology. Timely identification of the genetic causes is useful for an early diagnosis. Parkinson’s disease (PD) is the most frequent neurodegenerative movement disorder; it is associated with the presence of Lewy bodies (LBs) and genetic factors are involved in its pathogenesis. Several studies have indicated that the expression of target genes in patients with PD is inversely related to cancer development; this phenomenon has been named “inverse comorbidity”. The present study was undertaken to evaluate whether a genetic dysregulation occurs in opposite directions in patients with PD or PCa. In the present study, next-generation sequencing (NGS) transcriptome analysis was used to assess whether a genetic dysregulation in opposite directions occurs in patients with PD or PCa. The genes SLC30A1, ADO, SRGAP2C, and TBC1D12 resulted up-regulated in patients with PD compared to healthy donors as controls and down-regulated in patients with PCa compared with the same control group. These results support the hypothesis of the presence of inverse comorbidity between PD and PCa.

Genetic susceptibility of CYP1A1 gene and risk of pesticide exposure in prostate cancer

2020 ◽  
Vol 29 (4) ◽  
pp. 429-440
Author(s):  
Amar Abhishek ◽  
Nasreen Ghaji Ansari ◽  
Vishwajeet Singh ◽  
Rahul Janak Sinha ◽  
Prabhakar Mishra ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Stress Level ◽  
Genetic Factors ◽  
Pesticide Exposure ◽  
High Stress ◽  
P Value ◽  
Specific Pcr ◽  
Cyp1a1 Gene ◽  
High Stress Level ◽  
High Level

BACKGROUND: The etiology of prostate cancer (PCa) is multi-factorial including environmental and genetic factors. Present study evaluates the association between level of pesticides, stress level and CYP1A1 gene polymorphism with PCa patients. METHODS: A case control study was conducted with 102 PCa patients and age match symptomatic (n= 107) and asymptomatic benign prostatic hyperplasia (BPH, n= 70) patients. Pesticide level was characterized by Gas Chromatography. The oxidative stress and scavenging mechanisms were determined by biochemical method. Two polymorphisms of CYP1A1 gene, rs4646903 and rs1048943, were analyzed by polymerase chain reaction (PCR) followed by restriction fragment length polymorphism and allele specific PCR method. RESULTS: Higher level of pesticide namely beta-hexachlorocyclohexane (β-HCH), Malathion, Chlorpyrifos and Fenvalerate were found in PCa group (all p value: < 0.05). Kruskal Wallis H test depicted that level of β-HCH and Malathion significantly correlated with higher grade of PCa (all p< 0.05). The PCa Patients with simultaneously low antioxidant activity and high stress level tended to suffer worst clinical outcomes. Dominant model of rs4646903 and rs1048943 suggested that substitution is associated with a higher risk of PCa (OR: 2.2, CI: 1.6–3.8, p: 0.009 and OR: 1.95, CI: 1.1–3.4, p: 0.026; respectively) and this risk was also influenced by smoking and pesticide exposure. CONCLUSION: Environmental and genetic factors are reported to raise risk; person with high level of these pesticides especially in high risk genotype might be more susceptible to PCa.

612 INFLUENCE OF NON-GENETIC FACTORS ON INCIDENCE OF FAMILIAL PROSTATE CANCER. NATION-WIDE POPULATION-BASED STUDY IN PCBASE SWEDEN

2010 ◽  
Vol 9 (2) ◽  
pp. 204-205
Author(s):  
P.E. Stattin ◽  
H. Garmo ◽  
J. Adolfsson ◽  
A. Bill-Axelson ◽  
L. Holmberg ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Genetic Factors ◽  
Population Based ◽  
Population Based Study ◽  
Wide Population

scholarly journals Genetic factors regulating inflammation and DNA methylation associated with prostate cancer

2012 ◽  
Vol 16 (1) ◽  
pp. 56-61 ◽  
Author(s):  
M Ianni ◽  
E Porcellini ◽  
I Carbone ◽  
M Potenzoni ◽  
A M Pieri ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Dna Methylation ◽  
Genetic Factors

Environmental and genetic factors: a possible link with prostate cancer

1997 ◽  
Vol 79 (S2) ◽  
pp. 35-41 ◽  
Author(s):  
P. Ekman ◽  
Y. Pan ◽  
C. Li ◽  
J. Dich
Keyword(s):  
Prostate Cancer ◽  
Genetic Factors

scholarly journals Birth Characteristics and Risk of Prostate Cancer: the Contribution of Genetic Factors

2009 ◽  
Vol 18 (9) ◽  
pp. 2422-2426 ◽  
Author(s):  
S. Cnattingius ◽  
F. Lundberg ◽  
S. Sandin ◽  
H. Gronberg ◽  
A. Iliadou
Keyword(s):  
Prostate Cancer ◽  
Genetic Factors ◽  
Birth Characteristics

scholarly journals Genetic Factors Associated with Prostate Cancer Conversion from Active Surveillance to Treatment

2021 ◽  
Author(s):  
Yu Jiang ◽  
Travis J. Meyers ◽  
Adaeze A. Emeka, ◽  
Lauren Folgosa Cooley ◽  
Phillip R. Cooper ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Active Surveillance ◽  
Active Treatment ◽  
Genetic Factors ◽  
Genome Wide Association Study ◽  
Genetic Risk Score ◽  
Specific Antigen ◽  
Low Risk ◽  
Nucleotide Polymorphisms ◽  
Initial Management

Men diagnosed with low-risk prostate cancer (PC) are increasingly electing active surveillance (AS) as their initial management strategy. While this may reduce the side effects of treatment for prostate cancer, many men on AS eventually convert to active treatment. PC is one of the most heritable cancers, and genetic factors that predispose to aggressive tumors may help distinguish men who are more likely to discontinue AS. To investigate this, we undertook a multi-institutional genome-wide association study (GWAS) of 6,361 PC patients who initially elected AS and were followed over time for the potential outcome of conversion from AS to active treatment. In the GWAS we detected 18 single nucleotide polymorphisms (SNPs) associated with conversion, 15 of which were not previously associated with PC risk. We found two genes associated with conversion (MAST3, p = 6.9×10-7 and GAB2, p = 2.0×10-6). Moreover, increasing values of a previously validated 269-SNP genetic risk score (GRS) for PC was positively associated with conversion (e.g., comparing the highest to the two middle deciles gave a hazard ratio [HR] = 1.13; 95% Confidence Interval [CI]= 0.94-1.36); whereas, decreasing values of a 36-variant GRS for prostate-specific antigen (PSA) levels were positively associated with conversion (e.g., comparing the lowest to the two middle deciles gave a HR = 1.25; 95% CI, 1.04-1.50). These results suggest that germline genetics may help inform and individualize the decision of AS-or the intensity of monitoring on AS-versus treatment for the initial management of patients with low-risk PC.

Sign in / Sign up

Export Citation Format

Share Document